Stay updated on Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3. This appears to be an internal version update with no changes to study content or eligibility.
    Difference
    0.1%
    Check dated 2026-03-11T17:57:20.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    34 days ago
    Change Detected
    Summary
    Revision: v3.4.2 has been added to the page. The prior government funding/operating status notice (v3.4.1) has been removed.
    Difference
    0.4%
    Check dated 2026-02-11T09:59:57.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    Added a site-wide funding-status notice about a lapse in government funding with references to cc.nih.gov and opm.gov. Updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:55:46.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Added a Show glossary option; introduced the 'Revision: v3.4.0' label and standardized the QC update label to 'Last Update Submitted that Met QC Criteria'. Standardized capitalization for FEAR Act-related text across the page.
    Difference
    0.2%
    Check dated 2026-01-28T05:45:51.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.3 to v3.3.4. No study details, eligibility criteria, or results are changed.
    Difference
    0.1%
    Check dated 2026-01-14T03:12:48.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Locations sections were consolidated under a single 'Locations' header and now list California, District of Columbia, Illinois, Missouri, New York, and Texas; the HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.
    Difference
    0.8%
    Check dated 2025-12-23T10:18:06.000Z thumbnail image

Stay in the know with updates to Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab in High-Risk Ocular Melanoma Clinical Trial page.